BGC
GSK icon

Beutel, Goodman & Co’s GSK GSK Stock Holding History

Beutel, Goodman & Co’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607K Buy
11,584
+954
+9% +$50.5K ﹤0.01% 113
2026
Q1 		$586K Sell
10,630
-3,690
-26% -$200K ﹤0.01% 110
2025
Q4 		$702K Sell
14,320
-3,370
-19% -$157K ﹤0.01% 109
2025
Q3 		$763K Buy
17,690
+240
+1% +$9.38K ﹤0.01% 107
2025
Q2 		$670K Buy
17,450
+4,670
+37% +$178K ﹤0.01% 106
2025
Q1 		$495K Buy
12,780
+80
+0.6% +$2.93K ﹤0.01% 115
2024
Q4 		$429K Sell
12,700
-590
-4% -$21.2K ﹤0.01% 68
2024
Q3 		$543K Buy
13,290
+130
+1% +$5.32K ﹤0.01% 67
2024
Q2 		$506K Hold
13,160
– – ﹤0.01% 68
2024
Q1 		$564K Buy
13,160
+110
+0.8% +$4.54K ﹤0.01% 66
2023
Q4 		$483K Buy
13,050
+4,620
+55% +$166K ﹤0.01% 67
2023
Q3 		$305K Buy
8,430
+20
+0.2% +$710 ﹤0.01% 66
2023
Q2 		$299K Buy
8,410
+1,260
+18% +$45.2K ﹤0.01% 65
2023
Q1 		$254K Buy
7,150
+920
+15% +$32.2K ﹤0.01% 65
2022
Q4 		$218K Sell
6,230
-3,100
-33% -$103K ﹤0.01% 67
2022
Q3 		$274K Sell
9,330
-890
-9% -$33.7K ﹤0.01% 64
2022
Q2 		$556K Sell
10,220
-344
-3% -$19K ﹤0.01% 62
2022
Q1 		$575K Buy
10,564
+776
+8% +$42.1K ﹤0.01% 60
2021
Q4 		$539K Buy
9,788
+804
+9% +$41.8K ﹤0.01% 57
2021
Q3 		$429K Hold
8,984
– – ﹤0.01% 58
2021
Q2 		$447K Buy
8,984
+880
+11% +$42.3K ﹤0.01% 59
2021
Q1 		$361K Buy
8,104
+7,136
+737% +$324K ﹤0.01% 60
2020
Q4 		$44K Buy
968
+304
+46% +$14K ﹤0.01% 65
2020
Q3 		$31K Buy
+664
New +$33.3K ﹤0.01% 65
2020
Q1 		– Sell
-284,326
Closed -$16.7M – 67
2019
Q4 		$16.7M Sell
284,326
-60,261
-17% -$3.35M 0.1% 53
2019
Q3 		$14M Buy
+344,587
New +$17.7M 0.1% 52

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Beutel, Goodman & Co's GSK Position: Q2 2026 in Review

Beutel, Goodman & Co increased its GSK (GSK) stake by 9% in Q2 2026, buying an estimated $50.5K and bringing the position to 11,584 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #113.

Beutel, Goodman & Co first reported a position in GSK in Q3 2019 and has held it in 26 quarters since. The position peaked at $16.7M in Q4 2019. 1,039 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Beutel, Goodman & Co held 11,584 shares of GSK worth $607K as of Q2 2026.
  • Beutel, Goodman & Co bought 954 GSK shares in Q2 2026, an estimated $50.5K.
  • GSK made up ﹤0.01% of Beutel, Goodman & Co's portfolio in Q2 2026, its #113 holding.
  • Beutel, Goodman & Co first reported a position in GSK in Q3 2019 and has held it in 26 quarters since.
  • Beutel, Goodman & Co's GSK position peaked at $16.7M in Q4 2019.
  • 1,039 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Beutel, Goodman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.